X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs DR. REDDYS LAB - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD DR. REDDYS LAB WYETH LTD/
DR. REDDYS LAB
 
P/E (TTM) x 27.7 31.4 88.3% View Chart
P/BV x 5.3 3.4 159.0% View Chart
Dividend Yield % 1.3 0.8 162.6%  

Financials

 WYETH LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    WYETH LTD
Mar-13
DR. REDDYS LAB
Mar-18
WYETH LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,0442,788 37.5%   
Low Rs8181,902 43.0%   
Sales per share (Unadj.) Rs298.6860.8 34.7%  
Earnings per share (Unadj.) Rs57.257.1 100.3%  
Cash flow per share (Unadj.) Rs58.4122.0 47.9%  
Dividends per share (Unadj.) Rs17.0020.00 85.0%  
Dividend yield (eoy) %1.80.9 214.0%  
Book value per share (Unadj.) Rs249.5757.7 32.9%  
Shares outstanding (eoy) m22.72165.91 13.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.12.7 114.5%   
Avg P/E ratio x16.341.1 39.6%  
P/CF ratio (eoy) x15.919.2 82.9%  
Price / Book Value ratio x3.73.1 120.6%  
Dividend payout %29.735.0 84.7%   
Avg Mkt Cap Rs m21,157389,034 5.4%   
No. of employees `0000.523.5 2.1%   
Total wages/salary Rs m40032,149 1.2%   
Avg. sales/employee Rs Th13,787.46,070.8 227.1%   
Avg. wages/employee Rs Th813.01,366.6 59.5%   
Avg. net profit/employee Rs Th2,643.3402.5 656.7%   
INCOME DATA
Net Sales Rs m6,783142,810 4.7%  
Other income Rs m3531,552 22.7%   
Total revenues Rs m7,136144,362 4.9%   
Gross profit Rs m1,61723,512 6.9%  
Depreciation Rs m2710,772 0.2%   
Interest Rs m6788 0.7%   
Profit before tax Rs m1,93813,504 14.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6324,380 14.4%   
Profit after tax Rs m1,3019,468 13.7%  
Gross profit margin %23.816.5 144.8%  
Effective tax rate %32.632.4 100.6%   
Net profit margin %19.26.6 289.2%  
BALANCE SHEET DATA
Current assets Rs m6,984104,984 6.7%   
Current liabilities Rs m2,05668,938 3.0%   
Net working cap to sales %72.625.2 287.8%  
Current ratio x3.41.5 223.1%  
Inventory Days Days9974 133.5%  
Debtors Days Days24104 23.1%  
Net fixed assets Rs m244104,385 0.2%   
Share capital Rs m227830 27.4%   
"Free" reserves Rs m5,441124,886 4.4%   
Net worth Rs m5,668125,716 4.5%   
Long term debt Rs m2525,089 0.1%   
Total assets Rs m7,901225,443 3.5%  
Interest coverage x353.318.1 1,948.1%   
Debt to equity ratio x00.2 2.2%  
Sales to assets ratio x0.90.6 135.5%   
Return on assets %16.54.5 363.3%  
Return on equity %22.97.5 304.7%  
Return on capital %34.09.7 350.8%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1572,623 0.0%   
Fx outflow Rs m2,67718,916 14.2%   
Net fx Rs m-2,66253,707 -5.0%   
CASH FLOW
From Operations Rs m92318,030 5.1%  
From Investments Rs m317-14,883 -2.1%  
From Financial Activity Rs m-481-4,440 10.8%  
Net Cashflow Rs m759-1,236 -61.4%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 5.4 209.3%  
FIIs % 7.2 35.3 20.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 30.4 15.3 198.7%  
Shareholders   21,978 75,885 29.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   CIPLA  PFIZER  ALKEM LABORATORIES  SUN PHARMA  SANOFI INDIA  

Compare WYETH LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WYETH LTD WITH

MARKET STATS